Method of treatment using ligand-immunogen conjugates

Details Method of treatment using ligand-immunogen conjugates Method of treatment using ligand-immunogen conjugates

2006-04-25

2006-04-25

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S194100, C424S085100, C424S085200, C424S085500, C424S085700, C514S249000, C514S253030, C514S255030, C514S258100

Reexamination Certificate

active

07033594

ABSTRACT:
A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

REFERENCES:
patent: 2816110 (1957-12-01), Sletzinger et al.
patent: 4713249 (1987-12-01), Schroder
patent: 5140104 (1992-08-01), Coughlin et al.
patent: 5266333 (1993-11-01), Cady et al.
patent: 5417982 (1995-05-01), Modi et al.
patent: 5547668 (1996-08-01), Kranz et al.
patent: 5552545 (1996-09-01), Pearce et al.
patent: 5583202 (1996-12-01), Zanetti
patent: 5672486 (1997-09-01), Soulillou
patent: 5688488 (1997-11-01), Low et al.
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 6335434 (2002-01-01), Guzaev et al.
patent: 217577 (1992-06-01), None
patent: WO 91/01146 (1991-02-01), None
patent: WO 91/07418 (1991-05-01), None
patent: WO 97/37690 (1997-10-01), None
patent: WO 97/41831 (1997-11-01), None
patent: WO 01/32207 (2001-05-01), None
Abstract of Easty et al, International journal of Cancer, 1999, vol. 84, pp 494-501.
Abstract of Walker-Daniels et al, Prostate, 1999, vol. 41, pp. 275-280.
Drummond et al, Vitamins and Hormones, 2000, vol. 60, pp. 285-332.
Insel, Annals of the New York Academy of Science, 1995, vol. 754, pp. 35-47.
Abstract of Mazzoni et al, Proc Annu Meet Am Assoc cancer Res, 1997, vol. 38, p. A558.
Abstract of Leamon et al, Journal of Drug Targeting, 1999, vol. 7, pp. 157-169.
Roberts et al, Journal of Medicinal Chemistry, 1973, vol. 16, pp. 697-699.
Roberts et al, Journal of Medicinal Chemistry, 1972, vol. 15, pp. 1310-1312.
Roberts et al, Journal of Medicinal Chemistry, 1971, vol. 14, pp. 125-130.
Weinstock et al, Journal of Medicinal Chemistry,1970, vol. 13, pp. 995-997.
Bock et al, Journal of Medicinal Chemistry, 1974, vol. 17, pp. 23-28.
Roberts et al, Journal of Medicinal Chemistry, 1974, vol. 17, pp. 219-222.
Lee et al, Journal of Medicinal Chemistry, 1974, vol. 17, pp. 326-330.
Kim et al, Journal of Medicinal Chemistry, 1975, vol. 18, pp. 776-780.
Nair et al, Journal of Medicinal Chemistry, 1976, vol. 19, pp. 825-829.
Plante et al, Journal of Medicinal Chemistry, 1976, vol. 19, pp. 1295-1299.
Hynes et al, Journal of Medicinal Chemistry, 1977, vol. 20, pp. 588-591.
Oatis et al, Journal of Medicinal Chemistry, 1977, vol. 20, pp. 1393-1396.
Nair et al, Journal of Medicinal Chemistry, 1978, vol. 21, pp. 673-677.
Nair et al, Journal of Medicinal Chemistry, 1979, vol. 22, pp. 850-858.
Nair et al, Journal of Medicinal Chemistry, 1980, vol. 23, pp. 59-65.
Nair et al, Journal of Medicinal Chemistry, 1981, vol. 24, pp. 1068-1073.
Temple, Journal of Medicinal Chemistry, 1982, vol. 25, pp. 161-166.
Nair et al, Journal of Medicinal Chemistry, 1983, vol. 26, pp. 135-140.
Nair et al, Journal of Medicinal Chemistry, 1983, vol. 26, pp. 605-607.
Nair et al, Journal of Medicinal Chemistry, 1983, vol. 26, pp. 1164-1168.
Composite Immunological Antibiotic (Abstract of CN 1044781C), K. Hasegawa et al., published Aug. 22, 1990.
“Redirection of T Cell-Mediated Cytotoxicity by a Recombinant Single-Chain Fv Molecule,” George, et al.,Journal of Immunology, 1994, 152: 1802.
“Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases,” Berd et al.,Cancer Research, 51, 2731-2734, May 15, 1991.
“Eliciting Hyperacute Xenograft Response to Treat Human Cancer; α(1,3) Galatosyltransferase Gene Therapy,” Link Jr. et al.,Anticancer Research, 18: 2301-2308 (1998).
“Use of Xenogenized (Modified) Tumor Cells For Treatment In Experimental Tumor and In Human Neoplasia,” Ben-Efraim et al.Biomed.&Pharmacother. 2000, 54, 268; 73.
“Immunotoxins—Entry into Cells and Mechanisms of Action,” Olsnes et al.,Immunology Today, vol. 10, No. 9, 1989, p. 291.
“Entry of Protein Toxins in Polarized Epithelial Cells,” Melby et al.,Cancer Research, 53: 1755-1760, Apr. 15, 1993.
“Redirecting Circulating Antibodies via Ligand-Hapten Conjugates Eliminates Target Cells In Vivo,” Lussow et al.,Journal of Immunotherapy, 19(4):257-265 (1996).
“Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten Conjugate Prolongs Cardiac Graft Survival,” Lussow et al.,Transplantation, vol. 62, No. 12, 1703-1708, Dec. 27, 1996.
“Targeting T Cells Against Brain Tumors With A Bispecific Ligand-Antibody Conjugate,” Roy et al.,Int J. Cancer, 76: 761-766, (1998).
“Intracerebral Bispecific Ligand-Antibody Conjugate Increases Survival of Animals Bearing Endogenously Arising Brain Tumors,” Patrick, et al.,Int. J. Cancer, 78: 470-479 (1998).
“Section 23.5: Immunization with Synthetic or Highly Purified Tumor Antigens,” Philip Livingston, De Vita, V.T.,Biologic Therapy of Cancer, 2d ed., Philadelphia, Lippincott, 1995, pp 680-687.
Guyre, et al., Increased Potency of Fc-receptor-targeted Antigens,Cancer Immunol. Immunotherapy, vol. 45, pp. 146-148, 1997.
Lanza, et al., Use of Antigenized Antibodies Containing CD4 Sequences to Generate Antibodies Able to Inhibit Syncytia Formation,FASEB J., abstract No. 2690, p. A1400, 1992.

Affiliated with

Also associated with

Rating

Method of treatment using ligand-immunogen conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment using ligand-immunogen conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using ligand-immunogen conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3528151